当前位置: 首页 > 详情页

Antagonism of toll-like receptor 2 attenuates the formation and progression of abdominal aortic aneurysm

文献详情

资源类型:

收录情况: ◇ SCIE ◇ CSCD-C

机构: [1]Chinese Acad Med Sci, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Mol Immunol & Pharmacol Grp, Beijing 100050, Peoples R China; [2]Peking Union Med Coll, Beijing 100050, Peoples R China; [3]Capital Med Univ, An Zhen Hosp, Beijing Inst Heart Lung & Blood Vessel Dis, Beijing 100029, Peoples R China
出处:
ISSN:

关键词: Abdominal aortss aneury DAMPS Vascular remodeling TLR2 Immune microenvironment

摘要:
Abdominal aortic aneurysm (AAA) is an inflammatory vascular disorder with high mortality. Accumulating evidence shows that toll-like receptor 2 (TLR2) plays a critical role in the regulation of wound-repairing process after tissue injury. We wondered if TLR2 signaling contributed to the pathogenesis of AAA and that targeting TLR2 would attenuate AAA development and progression. In this study, enhanced expression of TLR2 and its ligands were observed in human AAA tissue. Neutralization of TLR2 protected against AAA development and caused established AAA to regress in mouse models of AAA. In addition, TLR2-deficient mice also failed to develop AAA. The prophylactic and therapeutic effects of blocking TLR2 were accompanied by a significant resolution of inflammation and vascular remodeling, as indicated by the decreased expression or activity of MMP-2/9, alpha-SMA, inflammatory cytokines, and transcription factors NF-kappa B, AP-1 and STAT1/3 in AAA tissue. Mechanistically, blocking TLR2 decreased the expression and interaction of TLR2 and several endogenous ligands, which diminished chronic inflammation and vascular remodeling in the vascular tissue of AAA. Our studies indicate that the interactions between TLR2 and its endogenous ligands contribute to the pathogenesis of AAA and that targeting TLR2 offers great potential toward the development of therapeutic agents against AAA. (C) 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2014]版:
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 药学
JCR分区:
出版当年[2013]版:
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版]

第一作者:
第一作者机构: [1]Chinese Acad Med Sci, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Mol Immunol & Pharmacol Grp, Beijing 100050, Peoples R China; [2]Peking Union Med Coll, Beijing 100050, Peoples R China;
通讯作者:
通讯机构: [1]Chinese Acad Med Sci, Inst Mat Med, State Key Lab Bioact Subst & Funct Nat Med, Mol Immunol & Pharmacol Grp, Beijing 100050, Peoples R China; [2]Peking Union Med Coll, Beijing 100050, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:17010 今日访问量:0 总访问量:909 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院